Rezolute Investor Relations Material
Latest events
AGM 2024
Rezolute
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Rezolute Inc
Access all reports
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly those related to chronic glucose imbalances. The company's lead product, RZ358, is a human monoclonal antibody currently in clinical trials aimed at treating congenital hyperinsulinism, a rare pediatric disorder. Additionally, Rezolute is working on RZ402, an oral plasma kallikrein inhibitor, intended for the treatment of diabetic macular edema. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
RZLT
Country
πΊπΈ United States